Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339883 | 1.00 | COMT (0.47) | COMTHSD17B3FFAR1PLA2G2APLA2G5 | |
| SCHEMBL31514936 | 0.77 | COMT (0.70) | COMTALDH1A1KMT2A | |
| SCHEMBL6341409 | 0.76 | HSD17B3 (0.61) | HSD17B3FFAR1PLA2G2APLA2G5THRA | |
| SCHEMBL6345972 | 0.76 | HSD17B3 (0.61) | HSD17B3FFAR1PLA2G2APLA2G5THRA | |
| SCHEMBL31514938 | 0.74 | COMT (0.55) | COMTALDH1A1 | |
| SCHEMBL31514939 | 0.74 | COMT (0.50) | COMTALDH1A1HTT | |
| SCHEMBL31514940 | 0.74 | COMT (0.50) | COMTALDH1A1HTT | |
| SCHEMBL6346541 | 0.73 | MAPK1 (0.48) | COMTMEN1KMT2AATM | |
| SCHEMBL5677489 | 0.71 | HSD17B3 (0.67) | HSD17B3FFAR1PLA2G2APLA2G5ALDH1A1 | |
| SCHEMBL10352970 | 0.71 | HSD17B3 (0.67) | HSD17B3FFAR1PLA2G2APLA2G5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903114-B2 | Derivatives of naphthalene with COMT inhibiting activity | ORION CORPORATION (FI) | 2005-06-07 | — | — | US | disclosed |
| US-20040034011-A1 | Derivatives of naphthalene with comt inhibiting activity | ORION CORPORATION (FI) | 2004-02-19 | — | — | US | disclosed |
| EP-1317411-A1 | DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022551-A1 | DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034011-A1 | Derivatives of naphthalene with comt inhibiting activity | COMT, CYP1A1, CYP1B1 | COMT 1/4885HSD17B3 145/4885FFAR1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.